Know Cancer

or
forgot password

A Multicenter, Non-interventional, Post-authorization Study to Observe in Daily Clinical Practice the Treatment Duration of Patients Treated With Avastin (Bevacizumab) in 1st Line mCRC in Belgium


N/A
18 Years
N/A
Open (Enrolling)
Both
Colorectal Cancer

Thank you

Trial Information

A Multicenter, Non-interventional, Post-authorization Study to Observe in Daily Clinical Practice the Treatment Duration of Patients Treated With Avastin (Bevacizumab) in 1st Line mCRC in Belgium


Inclusion Criteria:



- adult patients =/<18 years of age

- metastatic colorectal cancer

- patients for whom the physician has prescribed bevacizumab [Avastin] for the
treatment of 1st line metastatic colorectal cancer

- patients, who have given written informed consent

Exclusion Criteria:

- hypersensitivity to recombinant human or humanised antibodies

- pregnancy or breast-feeding

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Observation of treatment duration in daily clinical practice

Outcome Time Frame:

Throughout study, approximately 34 months

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

Belgium: Federal Agency for Medicinal Products and Health Products

Study ID:

ML25117

NCT ID:

NCT01089413

Start Date:

January 2010

Completion Date:

June 2013

Related Keywords:

  • Colorectal Cancer
  • Colorectal Neoplasms

Name

Location